期刊簡介 | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱![]() | CURRENT PHARMACEUTICAL DESIGN LetPub Score 5.7
50 ratings
Rate
Reputation 6.4 Influence 4.4 Speed 8.5 | ||||||||||||||||||||
期刊簡稱 | CURR PHARM DESIGN | ||||||||||||||||||||
ISSN | 1381-6128 | ||||||||||||||||||||
E-ISSN | 1873-4286 | ||||||||||||||||||||
h-index | 140 | ||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||
自引率 (2023-2024) | 3.80%自引率趨勢 | ||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||
官方網站 | http://benthamscience.com/journal/index.php?journalID=cpd | ||||||||||||||||||||
在線稿件提交 | http://benthamscience.com/journal/authors-guidelines.php?journalID=cpd#top | ||||||||||||||||||||
開放訪問 | No | ||||||||||||||||||||
出版商 | Bentham Science Publishers B.V. | ||||||||||||||||||||
主題領域 | 医学 | ||||||||||||||||||||
出版國/地區 | NETHERLANDS | ||||||||||||||||||||
發行頻率 | 隔週刊行 | ||||||||||||||||||||
創刊年 | 1995 | ||||||||||||||||||||
每年文章數 | 276每年文章數趨勢 | ||||||||||||||||||||
黃金OA百分比 | 1.34% | ||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q2
| ||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1381-6128%5BISSN%5D | ||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Average 2 Month(s) | ||||||||||||||||||||
競爭力 * | 來自作者的數據: About 25% | ||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[CURRENT PHARMACEUTICAL DESIGN] 的評論 | 撰寫評論 |
作者: 十一米阳光 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-12-05 19:43:40 評論於 Hello, how long does it take for the external audit report to be delivered after it is submitted? ![]() ![]() |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 16:51:47 評論於 Currently, ORCID is optional, not mandatory. It is important to note that most publishers (including Elsevier, Wiley, Nature, Thomson Reuters) now require all researchers associated with their publications to use an ORCID iD. If an article is published without providing an ORCID ID, how can it be added? ORCID stands for Open Researcher and Contributor ID. The ORCID iD is a unique and persistent academic identifier for authors, distinguishing them from other researchers and recording all their relevant research activities. To add an ORCID iD for an author, you need to log in to their account and then link it within the account information settings ![]() ![]() |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 14:08:24 評論於 ORCID is the abbreviation for Open Researcher and Contributor ID, and it is a non-profit organization. ORCID ID is a unique and persistent academic identity for contributors, which distinguishes authors from other researchers and records all of the author's research activities. Researcher can register for an ORCID ID for free at https://orcid.org/signin by providing their name, email, and setting a password ![]() ![]() |
作者: Oswald Edie 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 22:20:35 評論於 Is it necessary to provide the ORCID ID of each author when submitting a manuscript? ![]() ![]() |
作者: Darlene Pepys 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 09:58:23 評論於 What is ORCID iD? How do I register? ![]() ![]() |
作者: fangsheyu 領域: 医学 審稿時間: 4.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-14 14:48:16 評論於 May I ask how much time you were given for the repair? The editorial department gave me a week. Is this a major repair or a minor one? I'm worried about graduating. ![]() ![]() |
作者: gliangw 領域: 医学 審稿時間: 3.0 month(s) 結果: 修改後接受 撰寫評論 |
2021-10-19 08:51:54 評論於 The IF announced in 2021 has already reached 3.116. Students with graduation requirements can consider submitting contributions. ![]() ![]() |
作者: BlueMaN 領域: 医学 審稿時間: 6.0 month(s) 結果: 拒稿 撰寫評論 |
2020-10-01 10:26:20 評論於 The manuscript was submitted on April 26, and it was rejected on September 30. It was revised twice. The revision comments raised were not complicated. I revised the manuscript easily according to the comments and resubmitted it. I thought it would be accepted. In the end, it was rejected because of lack of innovation. ![]() ![]() |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-18 19:08:32 評論於 The past was good, but the current drop is very scary. I want to return to a 3-point level next year, but it may be really difficult ![]() ![]() |
作者: 狮吼嘉勋 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2016-08-25 11:58:33 評論於 Submission success rate: 25.0 Experience sharing: Don't fail, if it drops below 3 points, then my article would be in vain... Praying ![]() ![]() |
作者: Anonymous 領域: 医药科学 審稿時間: 4.0 month(s) 結果: 待定&不明 撰寫評論 |
2016-08-25 10:41:47 評論於 Don't drop it, if it falls to 3 points, then this article is not a whitehead....Prayer ![]() ![]() |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2014-06-11 17:10:36 評論於 Submitted for six months, no news ![]() ![]() |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2013-07-01 18:17:44 評論於 It's too unpredictable. It fell a little compared to last year. Can we maintain a three-point difference next year? It doesn't seem reliable at all ![]() ![]() |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2012-10-24 20:28:39 評論於 This magazine is well-regarded in the industry and mostly features commissioned articles ![]() ![]() |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2012-10-11 19:37:06 評論於 This magazine is quite good in the industry, with a 25% acceptance rate, but there are not many domestic submissions. It is recommended to give it a try ![]() ![]() |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2012-09-02 20:56:42 評論於 Review speed: 2.0 | Submission hit rate: 25.0 Sharing experience: This magazine is a good one in the industry, but it is relatively difficult to get published. There are not many domestic submissions yet. It is recommended to give it a try ![]() ![]() |
作者: 上清欣悦 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2012-09-02 13:12:48 評論於 Review speed: 2.0 | Submission hit rate: 25.0 Experience sharing: This journal is a good one in the industry, but it is relatively difficult to get accepted, and there are not many domestic submissions. It is recommended to give it a try ![]() ![]() |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us